Portfolio

Medinfar
Pharmaceutical
EGF II | EGF III

Invested in
2023

INVESTMENT RATIONALE

Investment in a Portuguese-origin pharmaceutical group founded in 1970, and it is a leader in Portugal in the Consumer Health and Dermatology category. The Medinfar Group produces and markets its own brands, such as Halibut, Trifene, or Aero-OM, as well as licensed products in partnership with major global pharmaceutical companies.

STRATEGY

Support R&D investment in the areas of developing new pharmaceutical formulation and improving the production process.